Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00804310 · ClinicalTrials.gov registry record · Phase 1
Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by University of California, Davis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00804310 is a Phase 1 study that was terminated before completion, run by University of California, Davis. The registered enrollment target is 5 participants.
The verdict
NCT00804310, a Phase 1 study, was terminated before completion, sponsored by University of California, Davis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib together with ixabepilone may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of lapatinib given together with ixabepilone in treating patients with advanced solid tumors.
Interventions
- DRUG lapatinib ditosylate
- DRUG ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00804310
The ClinicalTrials.gov registry entry for NCT00804310 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which lapatinib ditosylate is the first listed.
NCT00804310 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00804310 about?
NCT00804310 is a clinical study titled "Lapatinib and Ixabepilone in Treating Patients With Advanced Solid Tumors". RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving lapatinib t...
What is the current status of trial NCT00804310?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2009-08. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00804310?
The interventions under investigation include: lapatinib ditosylate (DRUG), ixabepilone (DRUG).
Who is sponsoring clinical trial NCT00804310?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.